Liquid biopsy-based diagnostic evaluation of hypermethylated CpG sites for ovarian cancer diagnosis.
Plasma methylation patterns may outperform CA-125 for ovarian cancer diagnosis, though larger prospective validation studies are needed.
This study evaluates plasma-based methylation profiling of specific CpG sites as a liquid biopsy diagnostic for ovarian cancer, reporting improved performance over CA-125. The methylation biomarker panel requires prospective validation in larger cohorts before clinical application.
What the study was
- Study design
- Diagnostic validation study — liquid biopsy methylation profiling for ovarian cancer
- Population
- Ovarian cancer patients and controls
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Molecular Oncology
Why it surfaced
CpG methylation liquid biopsy for ovarian cancer is relevant and timely; small pilot study limits evidence strength.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.